NCT04656847View on ClinicalTrials.gov

PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril

CompletedOBSERVATIONAL

Enrollment

504

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 5, 2021

Study Completion Date

October 18, 2021

Conditions

Coronary Artery DiseaseMyocardial InfarctionArterial Hypertension

Interventions

DRUG

in daily everyday routine practice

patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.

Trial Locations (1)

Unknown

Peoples' Friendship University of Russia, Moscow

All Listed Sponsors

lead

Servier Russia

INDUSTRY

NCT04656847 - PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril | Biotech Hunter | Biotech Hunter